Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
corticosteroids + cyclophosphamide + azathioprine
- Development stage
- Unknown
- Lead developer
- Yonsei University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This immunosuppressive treatment regimen is a step-wise therapeutic protocol developed by Yonsei University for the management of IgA nephropathy (IgAN) in patients at high risk of disease progression. The protocol involves an initial phase of corticosteroid therapy (such as methylprednisolone or prednisolone) for patients with persistent proteinuria despite intensive supportive care. For those who do not respond adequately or show rapid kidney function decline after three months, cyclophosphamide is added as an induction agent for a subsequent three-month period, followed by a transition to azathioprine for maintenance therapy. This sequential approach is designed to optimize renal outcomes while monitoring for treatment-related adverse events, addressing the conflicting evidence regarding intensive immunosuppression in IgAN seen in trials like STOP-IgAN and TESTING.
- Other names
- immunosuppressive treatment-Yonsei University-IgA nephropathyStep-wise immunosuppressive therapyCorticosteroids + Cyclophosphamide + Azathioprine
02
Targets
GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on corticosteroids + cyclophosphamide + azathioprine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on corticosteroids + cyclophosphamide + azathioprine.